Direct oral anticoagulants in the treatment of pulmonary embolism
Objective: The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs). Methods: PubMed was searched to identify relevant journal articles published through April 2017. Additional references were...
Saved in:
| Published in: | Current medical research and opinion Vol. 34; no. 1; pp. 131 - 140 |
|---|---|
| Main Authors: | , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
Taylor & Francis
02.01.2018
|
| Subjects: | |
| ISSN: | 0300-7995, 1473-4877, 1473-4877 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Objective: The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs).
Methods: PubMed was searched to identify relevant journal articles published through April 2017. Additional references were obtained from articles discovered during the database search.
Results: Initial heparinization followed by long-term anticoagulation with vitamin K antagonists has been considered the mainstay for the treatment of PE. However, DOACs now offer comparably effective and potentially safer alternatives for both acute and long-term treatment of PE using a monotherapy approach without the need for initial heparinization for rivaroxaban or apixaban. Advantages to using DOACs include oral availability, rapid onset of action, minimal drug and food interactions, predictable pharmacokinetics, and lack of need for routine monitoring. Limitations of using these agents include a limited availability of assays to quickly and efficiently measure their anticoagulant effects and the lack of widely available reversal agents for the direct oral factor Xa inhibitors; although idarucizumab has recently been approved for the reversal of dabigatran's anticoagulant effects.
Conclusions: Advantages to using DOACs render them an attractive alternative to conventional therapy in PE treatment that may simplify acute and long-term treatment paradigms, improve patient outcomes, and increase patient compliance. However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues. |
|---|---|
| AbstractList | Objective: The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs).
Methods: PubMed was searched to identify relevant journal articles published through April 2017. Additional references were obtained from articles discovered during the database search.
Results: Initial heparinization followed by long-term anticoagulation with vitamin K antagonists has been considered the mainstay for the treatment of PE. However, DOACs now offer comparably effective and potentially safer alternatives for both acute and long-term treatment of PE using a monotherapy approach without the need for initial heparinization for rivaroxaban or apixaban. Advantages to using DOACs include oral availability, rapid onset of action, minimal drug and food interactions, predictable pharmacokinetics, and lack of need for routine monitoring. Limitations of using these agents include a limited availability of assays to quickly and efficiently measure their anticoagulant effects and the lack of widely available reversal agents for the direct oral factor Xa inhibitors; although idarucizumab has recently been approved for the reversal of dabigatran's anticoagulant effects.
Conclusions: Advantages to using DOACs render them an attractive alternative to conventional therapy in PE treatment that may simplify acute and long-term treatment paradigms, improve patient outcomes, and increase patient compliance. However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues. The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs).OBJECTIVEThe objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs).PubMed was searched to identify relevant journal articles published through April 2017. Additional references were obtained from articles discovered during the database search.METHODSPubMed was searched to identify relevant journal articles published through April 2017. Additional references were obtained from articles discovered during the database search.Initial heparinization followed by long-term anticoagulation with vitamin K antagonists has been considered the mainstay for the treatment of PE. However, DOACs now offer comparably effective and potentially safer alternatives for both acute and long-term treatment of PE using a monotherapy approach without the need for initial heparinization for rivaroxaban or apixaban. Advantages to using DOACs include oral availability, rapid onset of action, minimal drug and food interactions, predictable pharmacokinetics, and lack of need for routine monitoring. Limitations of using these agents include a limited availability of assays to quickly and efficiently measure their anticoagulant effects and the lack of widely available reversal agents for the direct oral factor Xa inhibitors; although idarucizumab has recently been approved for the reversal of dabigatran's anticoagulant effects.RESULTSInitial heparinization followed by long-term anticoagulation with vitamin K antagonists has been considered the mainstay for the treatment of PE. However, DOACs now offer comparably effective and potentially safer alternatives for both acute and long-term treatment of PE using a monotherapy approach without the need for initial heparinization for rivaroxaban or apixaban. Advantages to using DOACs include oral availability, rapid onset of action, minimal drug and food interactions, predictable pharmacokinetics, and lack of need for routine monitoring. Limitations of using these agents include a limited availability of assays to quickly and efficiently measure their anticoagulant effects and the lack of widely available reversal agents for the direct oral factor Xa inhibitors; although idarucizumab has recently been approved for the reversal of dabigatran's anticoagulant effects.Advantages to using DOACs render them an attractive alternative to conventional therapy in PE treatment that may simplify acute and long-term treatment paradigms, improve patient outcomes, and increase patient compliance. However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues.CONCLUSIONSAdvantages to using DOACs render them an attractive alternative to conventional therapy in PE treatment that may simplify acute and long-term treatment paradigms, improve patient outcomes, and increase patient compliance. However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues. The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants (DOACs). PubMed was searched to identify relevant journal articles published through April 2017. Additional references were obtained from articles discovered during the database search. Initial heparinization followed by long-term anticoagulation with vitamin K antagonists has been considered the mainstay for the treatment of PE. However, DOACs now offer comparably effective and potentially safer alternatives for both acute and long-term treatment of PE using a monotherapy approach without the need for initial heparinization for rivaroxaban or apixaban. Advantages to using DOACs include oral availability, rapid onset of action, minimal drug and food interactions, predictable pharmacokinetics, and lack of need for routine monitoring. Limitations of using these agents include a limited availability of assays to quickly and efficiently measure their anticoagulant effects and the lack of widely available reversal agents for the direct oral factor Xa inhibitors; although idarucizumab has recently been approved for the reversal of dabigatran's anticoagulant effects. Advantages to using DOACs render them an attractive alternative to conventional therapy in PE treatment that may simplify acute and long-term treatment paradigms, improve patient outcomes, and increase patient compliance. However, questions remain pertaining to the use of DOACs in PE patients with high-risk features and in cancer patients and fragile populations. Clinical studies are under way to address many of these issues. |
| Author | Spyropoulos, Alex C. Eldredge, Joanna B. |
| Author_xml | – sequence: 1 givenname: Joanna B. surname: Eldredge fullname: Eldredge, Joanna B. organization: Department of Internal Medicine, Northwell Health System, Lenox Hill Hospital – sequence: 2 givenname: Alex C. surname: Spyropoulos fullname: Spyropoulos, Alex C. email: Aspyropoul@northwell.edu organization: Hofstra Northwell School of Medicine, Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health System, Lenox Hill Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28771049$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkMtOwzAQRS0EgrbwCaAs2aT4kTSx2IDKU0JiA2vLccZg5NjFdoT4e1y13bCA1Yw0587cuVO077wDhE4JnhPc4gvMMG44r-cUk2ZO2KKitNlDE1I1rKzaptlHkzVTrqEjNI3xA2NCW84P0RHNc4IrPkHXNyaASoUP0hbSJaO8fBtt7mJhXJHeoUgBZBrAZUgXq9EO3snwXcDQeWvicIwOtLQRTrZ1hl7vbl-WD-XT8_3j8vqpVBWjqaS6p6rFNdUgFe44yLbnmmqqVLdQtNd1DZlZVJJjaOpOcdKpjkHTVartWc9m6HyzdxX85wgxicFEBTZ7BT9GQTitW17VjGT0bIuO3QC9WAUzZMti93YGLjeACj7GAFook2Qy3qUgjRUEi3XIYheyWIcstiFndf1LvTvwn-5qozNO-zDILx9sL5L8tj7oIJ0yUbC_V_wARgOUDw |
| CitedBy_id | crossref_primary_10_1183_23120541_00184_2018 crossref_primary_10_1016_j_eclinm_2025_103389 crossref_primary_10_1016_j_ccep_2024_12_003 crossref_primary_10_7759_cureus_22113 crossref_primary_10_1177_0009922819881208 crossref_primary_10_1016_j_iccl_2023_02_001 crossref_primary_10_1055_s_0041_1725059 crossref_primary_10_1097_MJT_0000000000001605 crossref_primary_10_1177_14782715241311959 crossref_primary_10_5761_atcs_ra_19_00158 |
| Cites_doi | 10.1001/archinternmed.2010.199 10.1016/S0140-6736(11)60824-6 10.1016/0735-1097(92)90002-5 10.1182/asheducation-2013.1.464 10.1161/CIRCULATIONAHA.114.013445 10.1371/journal.pone.0144856 10.1160/TH09-05-0327 10.1016/S2352-3026(15)00257-4 10.1161/CIRCULATIONAHA.116.022307 10.1186/s12959-015-0071-z 10.1056/NEJMoa0906598 10.1160/TH16-04-0271 10.1111/bjh.13810 10.1186/s13256-016-1135-9 10.6004/jnccn.2015.0133 10.1160/TH16-06-0486 10.1111/acem.12585 10.1185/03007995.2013.879439 10.1378/chest.121.3.877 10.1056/NEJMoa1007903 10.1016/j.amepre.2009.12.017 10.1186/1477-9560-11-21 10.1093/eurheartj/ehu283 10.1016/j.chest.2015.11.026 10.1016/j.thromres.2014.11.008 10.1016/S2352-3026(16)30057-6 10.1586/ehm.13.11 10.1111/jth.12146 10.1056/NEJMoa1302507 10.1160/TH15-06-0452 10.1007/s11739-015-1249-x 10.1634/theoncologist.2011-0323 10.1111/acem.13072 10.1056/NEJMoa1113572 10.1056/NEJMoa1607887 10.1056/NEJMoa1306638 10.1161/CIRCULATIONAHA.113.004450 10.1016/j.thromres.2015.07.011 10.1371/journal.pone.0119043 10.1200/JOP.2015.004473 10.1056/NEJMoa1502000 10.1161/JAHA.115.002340 10.1111/j.1538-7836.2011.04388.x 10.1016/j.ijcard.2015.03.370 10.1016/0140-6736(93)90274-K 10.1161/CIRCULATIONAHA.111.029017 10.1056/NEJM199205073261902 10.1164/rccm.200506-862OC 10.1016/S2352-3026(16)30080-1 10.1080/21548331.2015.1099412 10.1016/S0140-6736(11)61904-1 10.1111/j.1538-7836.2006.02073.x 10.1160/TH16-03-0224 10.1186/1471-2342-5-6 10.1093/cvr/cvu082.154 |
| ContentType | Journal Article |
| Copyright | 2017 Informa UK Limited, trading as Taylor & Francis Group 2017 |
| Copyright_xml | – notice: 2017 Informa UK Limited, trading as Taylor & Francis Group 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1080/03007995.2017.1364227 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1473-4877 |
| EndPage | 140 |
| ExternalDocumentID | 28771049 10_1080_03007995_2017_1364227 1364227 |
| Genre | Review Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 00X 03L 0R~ 29F 4.4 5GY 5RE 6J9 6PF AAGDL AALUX AAMIU AAPUL AAQRR AAWTL ABBKH ABEIZ ABIVO ABJNI ABLIJ ABLJU ABLKL ABOCM ABUPF ABWVI ABXYU ACENM ACGFO ACGFS ACGOD ACIEZ ADCVX ADRBQ AECIN AENEX AEOZL AFRVT AGDLA AGFJD AGRBW AGYJP AHMBA AIJEM AIRBT AKBVH ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AMDAE AQTUD BABNJ BLEHA BOHLJ CCCUG CS3 DKSSO DU5 EBS EJD F5P H13 HZ~ KRBQP KSSTO KWAYT KYCEM L7B M4Z O9- P2P RNANH RVRKI RWL SJN TAE TASJS TBQAZ TDBHL TERGH TFDNU TFL TFW TUROJ UEQFS V1S ~1N AAYXX CITATION .55 .GJ 34G 39C 53G 7X7 88E 88I 8AF 8AO 8FI 8FJ 8R4 8R5 AALIY AAORF AAPXX ABBAB ABUWG ABWCV ABZEW ACKZS ACOPL ADBBV ADFOM ADFZZ ADYSH AEIIZ AFKRA AFLEI AJVHN ALIPV AZQEC BENPR BPHCQ BRMBE BVXVI CAG CCPQU CGR COF CUY CVF CYYVM CZDIS DRXRE DWQXO DWTOO ECM EIF EMOBN FYUFA GNUQQ HCIFZ HMCUK IPNFZ J5H JENTW LJTGL M1P M2P M2Q M44 NPM NUSFT PHGZT PQQKQ PROAC PSQYO Q2X QQXMO RIG S0X UKHRP X7M ZGI 7X8 |
| ID | FETCH-LOGICAL-c432t-2fd2c8052feac0b9ea8d9f2f2ccb6c2df55e2fd64a90e75bc91bcb3e7b4c8d3d3 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 10 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000428725800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0300-7995 1473-4877 |
| IngestDate | Sun Nov 09 10:51:46 EST 2025 Thu Apr 03 07:10:34 EDT 2025 Sat Nov 29 03:11:54 EST 2025 Tue Nov 18 20:44:36 EST 2025 Mon Oct 20 23:47:40 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Pulmonary embolism direct oral anticoagulants treatment deep vein thrombosis venous thromboembolism |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c432t-2fd2c8052feac0b9ea8d9f2f2ccb6c2df55e2fd64a90e75bc91bcb3e7b4c8d3d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 28771049 |
| PQID | 1925894531 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | crossref_citationtrail_10_1080_03007995_2017_1364227 proquest_miscellaneous_1925894531 pubmed_primary_28771049 informaworld_taylorfrancis_310_1080_03007995_2017_1364227 crossref_primary_10_1080_03007995_2017_1364227 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-01-02 |
| PublicationDateYYYYMMDD | 2018-01-02 |
| PublicationDate_xml | – month: 01 year: 2018 text: 2018-01-02 day: 02 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Current medical research and opinion |
| PublicationTitleAlternate | Curr Med Res Opin |
| PublicationYear | 2018 |
| Publisher | Taylor & Francis |
| Publisher_xml | – name: Taylor & Francis |
| References | Amin A. (CIT0062) 2016; 16 CIT0030 CIT0032 (CIT0017) 2015 CIT0031 CIT0034 CIT0033 (CIT0020) 2016 (CIT0053) 2015 CIT0036 CIT0035 CIT0038 CIT0037 CIT0039 CIT0041 CIT0040 CIT0043 CIT0042 CIT0001 CIT0045 CIT0044 CIT0003 CIT0047 CIT0002 CIT0046 CIT0005 CIT0049 CIT0004 CIT0048 CIT0007 CIT0006 CIT0009 CIT0008 Meyer G (CIT0012) 2014; 371 CIT0050 CIT0052 CIT0051 CIT0010 (CIT0019) 2016 CIT0054 CIT0056 CIT0011 CIT0055 CIT0014 CIT0058 CIT0013 CIT0057 CIT0016 CIT0015 CIT0059 CIT0061 (CIT0018) 2016 CIT0060 CIT0021 CIT0023 CIT0022 CIT0025 CIT0024 CIT0027 CIT0026 CIT0029 CIT0028 |
| References_xml | – ident: CIT0011 doi: 10.1001/archinternmed.2010.199 – ident: CIT0013 doi: 10.1016/S0140-6736(11)60824-6 – ident: CIT0009 doi: 10.1016/0735-1097(92)90002-5 – ident: CIT0016 doi: 10.1182/asheducation-2013.1.464 – ident: CIT0055 doi: 10.1161/CIRCULATIONAHA.114.013445 – ident: CIT0031 doi: 10.1371/journal.pone.0144856 – ident: CIT0021 doi: 10.1160/TH09-05-0327 – ident: CIT0037 doi: 10.1016/S2352-3026(15)00257-4 – ident: CIT0061 doi: 10.1161/CIRCULATIONAHA.116.022307 – ident: CIT0038 doi: 10.1186/s12959-015-0071-z – volume: 16 start-page: 531 year: 2016 ident: CIT0062 publication-title: Ochsner J – ident: CIT0023 doi: 10.1056/NEJMoa0906598 – ident: CIT0024 doi: 10.1160/TH16-04-0271 – ident: CIT0059 doi: 10.1111/bjh.13810 – ident: CIT0051 doi: 10.1186/s13256-016-1135-9 – ident: CIT0041 doi: 10.6004/jnccn.2015.0133 – volume: 371 start-page: 581 year: 2014 ident: CIT0012 publication-title: N Engl J Med – ident: CIT0047 doi: 10.1160/TH16-06-0486 – ident: CIT0027 doi: 10.1111/acem.12585 – ident: CIT0007 doi: 10.1185/03007995.2013.879439 – ident: CIT0003 doi: 10.1378/chest.121.3.877 – ident: CIT0026 doi: 10.1056/NEJMoa1007903 – ident: CIT0001 doi: 10.1016/j.amepre.2009.12.017 – ident: CIT0049 doi: 10.1186/1477-9560-11-21 – ident: CIT0006 doi: 10.1093/eurheartj/ehu283 – ident: CIT0005 doi: 10.1016/j.chest.2015.11.026 – ident: CIT0028 doi: 10.1016/j.thromres.2014.11.008 – ident: CIT0046 doi: 10.1016/S2352-3026(16)30057-6 – volume-title: Pradaxa (dabigatran etexilate mesylate) capsules for oral use. Full prescribing information year: 2015 ident: CIT0017 – ident: CIT0060 doi: 10.1586/ehm.13.11 – ident: CIT0015 doi: 10.1111/jth.12146 – ident: CIT0029 doi: 10.1056/NEJMoa1302507 – ident: CIT0048 doi: 10.1160/TH15-06-0452 – ident: CIT0035 doi: 10.1007/s11739-015-1249-x – volume-title: Eliquis (apixaban) tablets for oral use. Full prescribing information year: 2016 ident: CIT0019 – ident: CIT0042 doi: 10.1634/theoncologist.2011-0323 – ident: CIT0039 doi: 10.1111/acem.13072 – ident: CIT0025 doi: 10.1056/NEJMoa1113572 – ident: CIT0057 doi: 10.1056/NEJMoa1607887 – ident: CIT0032 doi: 10.1056/NEJMoa1306638 – ident: CIT0022 doi: 10.1161/CIRCULATIONAHA.113.004450 – ident: CIT0044 doi: 10.1016/j.thromres.2015.07.011 – ident: CIT0050 doi: 10.1371/journal.pone.0119043 – ident: CIT0040 doi: 10.1200/JOP.2015.004473 – volume-title: Praxbind (idarucizumab) injection for intravenous use. Full prescribing information year: 2015 ident: CIT0053 – ident: CIT0052 doi: 10.1056/NEJMoa1502000 – volume-title: Savaysa (edoxaban) tablets for oral use. Full prescribing information year: 2016 ident: CIT0020 – ident: CIT0030 doi: 10.1161/JAHA.115.002340 – ident: CIT0014 doi: 10.1111/j.1538-7836.2011.04388.x – ident: CIT0036 doi: 10.1016/j.ijcard.2015.03.370 – ident: CIT0008 doi: 10.1016/0140-6736(93)90274-K – ident: CIT0054 doi: 10.1161/CIRCULATIONAHA.111.029017 – ident: CIT0004 doi: 10.1056/NEJM199205073261902 – ident: CIT0010 doi: 10.1164/rccm.200506-862OC – ident: CIT0033 doi: 10.1016/S2352-3026(16)30080-1 – ident: CIT0034 doi: 10.1080/21548331.2015.1099412 – ident: CIT0002 doi: 10.1016/S0140-6736(11)61904-1 – ident: CIT0043 doi: 10.1111/j.1538-7836.2006.02073.x – ident: CIT0058 doi: 10.1160/TH16-03-0224 – ident: CIT0056 doi: 10.1186/1471-2342-5-6 – volume-title: Xarelto (rivaroxaban) tablets for oral use. Full prescribing information year: 2016 ident: CIT0018 – ident: CIT0045 doi: 10.1093/cvr/cvu082.154 |
| SSID | ssj0012899 |
| Score | 2.2581472 |
| SecondaryResourceType | review_article |
| Snippet | Objective: The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral... The objective of this review is to examine the management strategies for pulmonary embolism (PE) with an emphasis of the role of direct oral anticoagulants... |
| SourceID | proquest pubmed crossref informaworld |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 131 |
| SubjectTerms | Administration, Oral Anticoagulants - therapeutic use deep vein thrombosis direct oral anticoagulants Factor Xa Inhibitors - therapeutic use Heparin - therapeutic use Humans Pulmonary embolism Pulmonary Embolism - drug therapy Risk Factors treatment venous thromboembolism |
| Title | Direct oral anticoagulants in the treatment of pulmonary embolism |
| URI | https://www.tandfonline.com/doi/abs/10.1080/03007995.2017.1364227 https://www.ncbi.nlm.nih.gov/pubmed/28771049 https://www.proquest.com/docview/1925894531 |
| Volume | 34 |
| WOSCitedRecordID | wos000428725800015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor and Francis Online Journals customDbUrl: eissn: 1473-4877 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0012899 issn: 0300-7995 databaseCode: TFW dateStart: 19720101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8NAEF60iHjx_aiPsoLXaLrZPPZYxOLF4qFib2F3sguFNilNKvjvnc0Leyg96DGQyWN2dh47M98Q8uALZYHFQsdICDBAgdARSgpHQhigwUYbllTDJsLRKJpMxHtdTZjXZZU2hjYVUESpq-3mlipvKuKeUC5di2NmC7NCW6fFGbP95Gj67dYcDz_bPIINJ6o8gutYkqaHZ9NT1qzTGnbpZg-0tETDo3_4h2NyWLuhdFDJzQnZ0ekp2X-rE-1nZFCpQmr79ykyH-VF2qH1aZHTaUrRa6RtiTrNDF2sZijPcvlN9Vxls2k-Pycfw5fx86tTT1twgHuscJhJGNgBBwZ1sauEllEiDDMMQAXAEuP7Gu8JuBSuDn0Foq9AeTpUHKLES7wL0kmzVF8RqiKBihaMBy5w1KYR94AZdIa0G2hQokt4w-UYaihyOxFjFvcbxNKaPbFlT1yzp0seW7JFhcWxjUD8XsK4KA9BTDWxJPa20N436x3jjrNpFJnqbJXH6BP7keCovLrkshKE9nMw_kSXjYvrP7z5hhzgZVSe87Bb0imWK31H9uCrmObLHtkNJ1GvlPIflGf1mg |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT-MwEB6xgBYusAsLlMdiJK5hg-M8fESICgT0VLTcrHhiS5VKitoUiX_PTB4VHBCH3XMyeYzH8_Y3AKextgwslgY-x4QCFEwDbXMd5JgmZLDJhhXNsIl0MMgeH_X7szDcVskxtG-AImpdzZubk9FdS9wfEsyQgcy4MyvlRi0lZfoNVmKytYyfP-z_XVQSOKBoKglhwDTdKZ7PHvPBPn1AL_3cB61tUX_zf_zFD9hoPVFx0YjOT1hy5RZ8v29r7dtw0WhDwUf4BfGfRCbnufVlNROjUpDjKBZd6mLixfN8TCKdT1-Fe7KT8Wj29Ase-lfDy-ugHbgQoIpkFUhfSOQZB57UcWi1y7NCe-klok1QFj6OHd2TqFyHLo0t6nOLNnKpVZgVURHtwHI5Kd0eCJtp0rXoIwxRkULNVITSkz_kwsSh1T1QHZsNtmjkPBRjbM470NKWPYbZY1r29OBsQfbcwHF8RaDfr6Gp6jyIb4aWmOgL2pNuwQ1tOq6k5KWbzGeG3OI404r0Vw92G0lYfA6FoOS1Kb3_D28-hrXr4f2dubsZ3B7AOl3K6rSPPITlajp3R7CKL9VoNv1dC_sbYT_43A |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3JTsMwEB2xCXFhX8pqJK6B4DiLjwioQEDFAQQ3K57YUqWSVk2KxN8zzlLBAXGAc-Is4-dZPOM3ACeh1I5YLPZsihEFKBh7UqfSSzGOyGCTDcvqZhNxr5e8vsrHppqwaMoqXQxta6KISle7xT3KbFsRd0a49B2PmSvMil2dluA8noV5cp0jB_Kn7ss0keDiiTqR4HtuTHuI56fHfDNP38hLf3ZBK1PUXfmHn1iF5cYPZRc1cNZgxuTrsPjQZNo34KLWhcwd4GckfQJM6rrW52XB-jkjt5FNa9TZ0LLRZECATscfzLzp4aBfvG3Cc_f66fLGa9oteCgCXnrcZhxdhwNLytjX0qRJJi23HFFHyDMbhobuiUQqfROHGuW5Rh2YWAtMsiALtmAuH-ZmB5hOJGlatAH6KEidJiJAbskbMn5kUMsOiFbKChsuctcSY6DOW8rSRjzKiUc14unA6XTYqCbj-G2A_DqFqqx2QWzdskQFv4w9budb0ZJzeZQ0N8NJocgpDhMpSHt1YLsGwvRzKAAln03I3T-8-QgWH6-66v62d7cHS3QlqfZ8-D7MleOJOYAFfC_7xfiwgvoncDT3jg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Direct+oral+anticoagulants+in+the+treatment+of+pulmonary+embolism&rft.jtitle=Current+medical+research+and+opinion&rft.au=Eldredge%2C+Joanna+B.&rft.au=Spyropoulos%2C+Alex+C.&rft.date=2018-01-02&rft.issn=0300-7995&rft.eissn=1473-4877&rft.volume=34&rft.issue=1&rft.spage=131&rft.epage=140&rft_id=info:doi/10.1080%2F03007995.2017.1364227&rft.externalDBID=n%2Fa&rft.externalDocID=10_1080_03007995_2017_1364227 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-7995&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-7995&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-7995&client=summon |